ERBB2 and gastric cancer: We stratified HER2-positive mGC patients (n = 13) of series 1 into low- (LS) and high-survival (HS) groups according to the median time of survival to investigate if one of the genes associated with HER2 overexpression may also affect the survival ((from GC diagnosis median OS 22 months (95%CI 12 to 27); from metastasis median OS: 19 months (95%CI 7 to 23)).